肝内胆汁淤积症血清胆汁酸谱的特征及研究进展

摘要/Abstract

摘要： 胆汁淤积性肝病是肝内外各种原因造成胆汁无法流入十二指肠而进入血液的病理状态。胆汁淤积性肝病的发病机制较为复杂,疾病分类多种多样,现有研究提示,胆汁酸谱作为胆汁淤积性肝病中的经典标志物,可在一定程度上反映疾病进程。本文就胆汁酸谱及影响胆汁酸代谢的因素进行综述,并总结部分典型肝内胆汁淤积症中血清胆汁酸谱的特征及差异,为通过胆汁酸各组分含量变化对肝内胆汁淤积症的诊断及鉴别诊断提供新的证据,为观察疾病进展及制定治疗方案提供新的思路。

关键词: 肝内胆汁淤积症, 胆汁酸谱, 胆汁酸代谢, 核受体, 肠道菌群

朱时帅, 芦曦. 肝内胆汁淤积症血清胆汁酸谱的特征及研究进展[J]. 肝脏, 2022, 27(6): 715-719.

参考文献

[1] Hilscher MB, Kamath PS, Eaton JE. Cholestatic Liver Diseases: A Primer for Generalists and Subspecialists.Mayo Clin Proc,2020,95(10):2263-2279.
[2] Cao X, Gao Y, Zhang W, et al. Cholestasis morbidity rate in first-hospitalized patients with chronic liver disease in Shanghai. Zhonghua Gan Zang Bing Za Zhi,2015,23(8):569-573.
[3] Onofrio FQ, Hirschfield GM. The Pathophysiology of Cholestasis and Its Relevance to Clinical Practice. Clin Liver Dis (Hoboken),2020,15(3):110-114.
[4] Chiang J, Ferrell JM. Bile acid receptors FXR and TGR5 signaling in fatty liver diseases and therapy. Am J Physiol Gastrointest Liver Physiol,2020,318(3):G554-G573.
[5] Zeng H, Umar S, Rust B, et al. Secondary Bile Acids and Short Chain Fatty Acids in the Colon: A Focus on Colonic Microbiome, Cell Proliferation, Inflammation, and Cancer. Int J Mol Sci,2019,20(5):1214.
[6] Lavoie J. Dynamics of hepatic and intestinal cholesterol and bile acid pathways: The impact of the animal model of estrogen deficiency and exercise training. World J Hepatol,2016,8(23):961.
[7] Jetter A, Kullak-Ublick GA. Drugs and hepatic transporters: A review. Pharmacol Res,2020,154:104234.
[8] Pan Q, Zhang X, Zhang L, et al. Solute Carrier Organic Anion Transporter Family Member 3A1 Is a Bile Acid Efflux Transporter in Cholestasis. Gastroenterology,2018,155(5):1578-1592.
[9] Kroll T, Prescher M, Smits S H J, et al. Structure and Function of Hepatobiliary ATP Binding Cassette Transporters. Chem Rev,2021,12;121(9):5240-5288.
[10] Ticho AL, Malhotra P, Dudeja PK, et al. Intestinal Absorption of Bile Acids in Health and Disease. Compr Physiol,2019,10(1):21-56.
[11] Beaudoin JJ, Brouwer K, Malinen M M. Novel insights into the organic solute transporter alpha/beta, OSTalpha/beta: From the bench to the bedside. Pharmacol Ther,2020,211:107542.
[12] Yamauchi Y, Rogers MA. Sterol Metabolism and Transport in Atherosclerosis and Cancer. Front Endocrinol (Lausanne),2018,19;9:509.
[13] Clayton PT. The effectiveness of correcting abnormal metabolic profiles. J Inherit Metab Dis,2020,43(1):2-13.
[14] Banales JM, Huebert RC, Karlsen T, et al. Cholangiocyte pathobiology. Nat Rev Gastroenterol Hepatol,2019,16(5):269-281.
[15] Jiao N, Baker SS, Chapa-Rodriguez A, et al. Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD. Gut,2018,67(10):1881-1891.
[16] Merk D, Sreeramulu S, Kudlinzki D, et al. Molecular tuning of farnesoid X receptor partial agonism. Nat Commun,2019,10(1):2915.
[17] Zhang Y, Jackson JP, St CRR, et al. Obeticholic acid, a selective farnesoid X receptor agonist, regulates bile acid homeostasis in sandwich-cultured human hepatocytes. Pharmacol Res Perspect,2017,5(4):e00329.
[18] Carazo A, Hyrsova L, Dusek J, et al. Acetylated deoxycholic (DCA) and cholic (CA) acids are potent ligands of pregnane X (PXR) receptor. Toxicol Lett,2017,265:86-96.
[19] Lickteig AJ, Csanaky IL, Pratt-Hyatt M, et al. Activation of Constitutive Androstane Receptor (CAR) in Mice Results in Maintained Biliary Excretion of Bile Acids Despite a Marked Decrease of Bile Acids in Liver. Toxicol Sci,2016,151(2):403-418.
[20] Minniti ME, Pedrelli M, Vedin LL, et al. Insights From Liver-Humanized Mice on Cholesterol Lipoprotein Metabolism and LXR-Agonist Pharmacodynamics in Humans. Hepatology,2020,72(2):656-670.
[21] Perino A, Demagny H, Velazquez-Villegas L, et al. Molecular Physiology of Bile Acid Signaling in Health, Disease, and Aging. Physiol Rev,2021,101(2):683-731.
[22] Quinn RA, Melnik AV, Vrbanac A, et al. Global chemical effects of the microbiome include new bile-acid conjugations. Nature,2020,579(7797):123-129.
[23] Schneider KM, Albers S, Trautwein C. Role of bile acids in the gut-liver axis. J Hepatol,2018,68(5):1083-1085.
[24] 范建高,徐正婕.酒精性肝病与胆汁淤积. 肝脏,2000,5(1):34.
[25] Bj?rkhaug ST, Skar V, Medhus AW, et al. Chronic alcohol overconsumption may alter gut microbial metabolism: a retrospective study of 71913 C-D-xylose breath test results. Microb Ecol Health Dis,2017,28(1):1301725.
[26] Hartmann P, Hochrath K, Horvath A, et al. Modulation of the intestinal bile acid/farnesoid X receptor/fibroblast growth factor 15 axis improves alcoholic liver disease in mice. Hepatology,2018,67(6):2150-2166.
[27] Zhu L, Baker RD, Zhu R, et al. Bile Acids and the Gut Microbiome as Potential Targets for NAFLD Treatment. J Pediatr Gastroenterol Nutr,2018,67(1):3-5.
[28] Dixon PH, Wadsworth CA, Chambers J, et al. A comprehensive analysis of common genetic variation around six candidate loci for intrahepatic cholestasis of pregnancy. Am J Gastroenterol,2014,109(1):76-84.
[29] Pataia V, Dixon PH, Williamson C. Pregnancy and bile acid disorders. Am J Physiol Gastrointest Liver Physiol,2017,313(1):G1-G6.
[30] Ren L, Song Q, Liu Y, et al. Probiotic Lactobacillus rhamnosus GG prevents progesterone metabolite epiallaopregnanolone sulfate-induced hepatic bile acid accumulation and liver injury. Biochem Biophys Res Commun,2019,520(1):67-72.
[31] Abu-Hayyeh S, Williamson C. Progesterone Metabolites as Farnesoid X Receptor Inhibitors. Dig Dis,2015,33(3):300-306.
[32] Song X, Vasilenko A, Chen Y, et al. Transcriptional dynamics of bile salt export pump during pregnancy: Mechanisms and implications in intrahepatic cholestasis of pregnancy. Hepatology,2014,60(6):1993-2007.
[33] Moscovitz JE, Kong B, Buckley K, et al. Restoration of enterohepatic bile acid pathways in pregnant mice following short term activation of Fxr by GW4064. Toxicol Appl Pharmacol,2016,310:60-67.
[34] Tribe RM, Dann AT, Kenyon AP, et al. Longitudinal profiles of 15 serum bile acids in patients with intrahepatic cholestasis of pregnancy. Am J Gastroenterol,2010,105(3):585-595.
[35] Bull LN, Thompson RJ. Progressive Familial Intrahepatic Cholestasis. Clin Liver Dis,2018,22(4):657-669.
[36] Aronson SJ, Bakker RS, Shi X, et al. Liver-directed gene therapy results in long-term correction of progressive familial intrahepatic cholestasis type 3 in mice. J Hepatol,2019,71(1):153-162.
[37] Takeyama Y, Uehara Y, Inomata S, et al. Alternative transporter pathways in patients with untreated early-stage and late-stage primary biliary cirrhosis. Liver Int,2009,29(3):406-414.
[38] Kojima H, Nies AT, K?nig J, et al. Changes in the expression and localization of hepatocellular transporters and radixin in primary biliary cirrhosis. J Hepatol,2003,39(5):693-702.
[39] Takeyama Y, Kanegae K, Inomata S, et al. Sustained upregulation of sodium taurocholate cotransporting polypeptide and bile salt export pump and downregulation of cholesterol 7α-hydroxylase in the liver of patients with end-stage primary biliary cirrhosis. Med Mol Morphol,2010,43(3):134-138.
[40] Li T, Apte U. Bile Acid Metabolism and Signaling in Cholestasis, Inflammation, and Cancer. Adv Pharmacol,2015,74:263-302.
[41] Chen W, Wei Y, Xiong A, et al. Comprehensive Analysis of Serum and Fecal Bile Acid Profiles and Interaction with Gut Microbiota in Primary Biliary Cholangitis. Clin Rev Allergy Immunol,2020,58(1):25-38.
[42] Mousa OY, Juran BD, Mccauley BM, et al. Bile Acid Profiles in Primary Sclerosing Cholangitis and their Ability to Predict Hepatic Decompensation. Hepatology,2021:74(1):281-295.
[43] Shah A, Macdonald GA, Morrison M, et al. Targeting the Gut Microbiome as a Treatment for Primary Sclerosing Cholangitis: A Conceptional Framework. Am J Gastroenterol,2020,115(6):814.
[44] Quraishi MN, Acharjee A, Beggs AD, et al. A Pilot Integrative Analysis of Colonic Gene Expression, Gut Microbiota, and Immune Infiltration in Primary Sclerosing Cholangitis-Inflammatory Bowel Disease: Association of Disease With Bile Acid Pathways. J Crohns Colitis,2020,14(7):935-947.